Characteristics and outcomes of patients screened for transcatheter mitral valve implantation: 1-year results from the CHOICE-MI registry

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 4,85 MB, PDF-dokument

  • Walid Ben Ali
  • Sebastian Ludwig
  • Alison Duncan
  • Jessica Weimann
  • Georg Nickenig
  • Tetsu Tanaka
  • Augustin Coisne
  • Andre Vincentelli
  • Raj Makkar
  • John G. Webb
  • Mariama Akodad
  • David W.M. Muller
  • Fabien Praz
  • Mirjam G. Wild
  • Jörg Hausleiter
  • Sachin S. Goel
  • Moritz Wyler von Ballmoos
  • Paolo Denti
  • Omar Chehab
  • Simon Redwood
  • Gry Dahle
  • Stephan Baldus
  • Matti Adam
  • Hendrik Ruge
  • Rüdiger Lange
  • Tsuyoshi Kaneko
  • Lionel Leroux
  • Nicolas Dumonteil
  • Didier Tchetche
  • Hendrik Treede
  • Michele Flagiello
  • Jean Francois Obadia
  • Thomas Walther
  • Maurizio Taramasso
  • Søndergaard, Lars
  • Sabine Bleiziffer
  • Tanja K. Rudolph
  • Neil Fam
  • Joerg Kempfert
  • Juan F. Granada
  • Gilbert H.L. Tang
  • Ralph Stephan von Bardeleben
  • Lenard Conradi
  • Thomas Modine
  • Daniel Kalbacher
  • Stefan Blankenberg
  • Benedikt Koell
  • Niklas Schofer
  • Dirk Westermann
  • Marcel Weber
  • CHOICE-MI Investigators

Aims: Transcatheter mitral valve implantation (TMVI) represents a novel treatment option for patients with mitral regurgitation (MR) unsuitable for established therapies. The CHOICE-MI registry aimed to investigate outcomes of patients undergoing screening for TMVI. Methods and results: From May 2014 to March 2021, patients with MR considered suboptimal candidates for transcatheter edge-to-edge repair (TEER) and at high risk for mitral valve surgery underwent TMVI screening at 26 centres. Characteristics and outcomes were investigated for patients undergoing TMVI and for TMVI-ineligible patients referred to bailout-TEER, high-risk surgery or medical therapy (MT). The primary composite endpoint was all-cause mortality or heart failure hospitalization after 1 year. Among 746 patients included (78.5 years, interquartile range [IQR] 72.0–83.0, EuroSCORE II 4.7% [IQR 2.7–9.7]), 229 patients (30.7%) underwent TMVI with 10 different dedicated devices. At 1 year, residual MR ≤1+ was present in 95.2% and the primary endpoint occurred in 39.2% of patients treated with TMVI. In TMVI-ineligible patients (n = 517, 69.3%), rates of residual MR ≤1+ were 37.2%, 100.0% and 2.4% after bailout-TEER, high-risk surgery and MT, respectively. The primary endpoint at 1 year occurred in 28.8% of patients referred to bailout-TEER, in 42.9% of patients undergoing high-risk surgery and in 47.9% of patients remaining on MT. Conclusion: This registry included the largest number of patients treated with TMVI to date. TMVI with 10 dedicated devices resulted in predictable MR elimination and sustained functional improvement at 1 year. In TMVI-ineligible patients, bailout-TEER and high-risk surgery represented reasonable alternatives, while MT was associated with poor clinical and functional outcomes.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Heart Failure
Vol/bind24
Udgave nummer5
Sider (fra-til)887-898
Antal sider12
ISSN1388-9842
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
This research was supported by a grant from the German Heart Foundation (DHS). Conflict of interest: W.B.A. received research grants from Medtronic and Edwards Lifesciences. S.L. was supported by a grant from the German Heart Foundation (DHS) and received travel compensation by Edwards Lifesciences. A.D. is a consultant for and has and received honoraria from Abbott Laboratories, Edward Lifesciences and Medtronic. G.H.L.T. is a physician proctor and consultant for Medtronic, consultant and TAVR physician advisory board member for Abbott Structural Heart, consultant for NeoChord and advisory board member for JenaValve. L.C. is advisory board member for Abbott, Medtronic and BostonScientific and has received personal fees from Edwards Lifesciences. All other authors have nothing to disclose. We would like to thank all the CHOICE-MI investigators for their invaluable contributions to this study. Open Access funding enabled and organized by Projekt DEAL. This research was supported by a grant from the German Heart Foundation (DHS). Conflict of interest: W.B.A. received research grants from Medtronic and Edwards Lifesciences. S.L. was supported by a grant from the German Heart Foundation (DHS) and received travel compensation by Edwards Lifesciences. A.D. is a consultant for and has and received honoraria from Abbott Laboratories, Edward Lifesciences and Medtronic. G.H.L.T. is a physician proctor and consultant for Medtronic, consultant and TAVR physician advisory board member for Abbott Structural Heart, consultant for NeoChord and advisory board member for JenaValve. L.C. is advisory board member for Abbott, Medtronic and BostonScientific and has received personal fees from Edwards Lifesciences. All other authors have nothing to disclose.

Funding Information:
: W.B.A. received research grants from Medtronic and Edwards Lifesciences. S.L. was supported by a grant from the German Heart Foundation (DHS) and received travel compensation by Edwards Lifesciences. A.D. is a consultant for and has and received honoraria from Abbott Laboratories, Edward Lifesciences and Medtronic. G.H.L.T. is a physician proctor and consultant for Medtronic, consultant and TAVR physician advisory board member for Abbott Structural Heart, consultant for NeoChord and advisory board member for JenaValve. L.C. is advisory board member for Abbott, Medtronic and BostonScientific and has received personal fees from Edwards Lifesciences. All other authors have nothing to disclose. Conflict of interest

Funding Information:
This research was supported by a grant from the German Heart Foundation (DHS).

Publisher Copyright:
© 2022 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

ID: 313704046